

ACCESS[®]

“Lack of innovation and access to medicines : only a problem of the “developing world”? The case of HIV and HCV in high income countries”


Pauline Londeix, Co-founder, Access (São Paulo/Paris)

« VANCOUVER and TRIPS 20 YEARS AFTER: BARRIERS TO ACCESS TO MEDICINES TODAY »

SIDE EVENT AT THE HUMAN RIGHTS COUNCIL, 31st SESSION

Friday, March the 11th, Geneva, Switzerland

Introduction



Prices of ARVs, the example of France



Medicine	Price per month (euros) /person	Price per year (euros) /person
Raltegravir	609,31	7311,72
Darunavir	731,46	8777,52

Cost of ARVs, a barrier to access, the example of the United Kingdom



Tenofovir disoproxil fumarate (TDF) vs Tenofovir alafenamide (TAF)




ACCESS[®]

2014, a turning point in the history of hepatitis C




Until 2013




Since 2014

ACCESS®

Standardized pricing (the example of the United States)



Standardized pricing (the example of France)



Real cost of production of HCV treatments

COSTS PER PERSON, FOR 12 WEEK COURSE OF HCV DAA

Agent	Daily Dose, mg	Overall Dose, for 12wk, g	Production cost estimate(US\$/g)	Predicted cost (US\$)
Ribavirin	1200	101	\$0.34 ^a	\$48 ^b
Daclatasvir	60	5	\$4.0	\$20
Sofosbuvir	400	34	\$3.0	\$101
MK-8742	50	4	\$11.0	\$44
MK-5172	100	8	\$8.9	\$74
Ledipasvir	90	8	\$11.6	\$93

Cost of production
≠ price

Price =
Cost of production
+ Margin profits


^acurrent mid-point cost of API from 3 Chinese suppliers

^b shows cost for 1200mg daily dose; \$41 for 1000mg daily dose of ribavirin

Tiered pricing an middle income countries

Low income countries & voluntary licenses

Gilead's license leaves out nearly 73 million people with HCV who will have to pay Gilead's high prices.




Source : Hepcoalition.org,
Octobre 2014

What could be the solutions ?

Can we wait for these patents to run out?

Patent Expiry Dates of DAAs



ACCESS[®]

Which solutions for excluded countries?

A fruitful negotiation according to the France Minister of Health



From 45 000€ to 41 000€ is it really a success?



Paris, le 20 novembre 2014

COMMUNIQUE DE PRESSE

**Mettre l'innovation au service des malades rapidement et au prix juste
(fixation du prix de la spécialité Sovaldi)**

Marisol TOURAINE, qui avait pris l'initiative de mobiliser les pays européens sur ce sujet, se félicite de cette négociation qui garantit l'accès à des soins de qualité et innovants, au meilleur coût pour la sécurité sociale et les patients.

Conclusion

ACCESS[®]

Thank you!

pauline.londeix@gmail.com

ACCESS[®]